Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease in General Practice

November 21, 2011 updated by: E. Bischoff, Radboud University Medical Center

Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease (COPD) in General Practice. A Randomized Controlled Trial Comparing Regular Practice Nurse Review, Self-management Education and Usual Care

In this randomized controlled trial, three contemporary modes for chronic obstructive pulmonary disease (COPD) management in Dutch general practices are compared for costs and effects:

  • usual general practitioner (GP) care (at patient's initiative);
  • regular practice nurse review; and
  • integrated self-management education.

All three interventions are based on existing guidelines, materials, and field experiences.

Study Overview

Detailed Description

Considering the ageing of the Dutch population and the current and increasing shortage of general practitioners (GPs), the capacity of primary healthcare is a major and growing concern. Delegation of care normally provided by GPs with care provided by trained practice nurses is now rapidly emerging for patients with chronic respiratory disease, i.e. asthma and chronic obstructive pulmonary disease (COPD). However, most general practices still provide care at initiative of the patient self, because of the lack in scientific evidence and the costs of implementing a regular care structure. Self-care by patients may be an alternative to alleviate the growing load on primary health care.

The following two main research questions are addressed in this study.

  • Does an integrated self-management education intervention for patients with COPD in general practice contribute to attaining long-term treatment targets, compared to regular monitoring by a practice nurse and usual GP care?
  • What is the cost-effectiveness of an integrated self-management education intervention for patients with COPD, compared to regular monitoring by a practice nurse and usual GP care?

Study Type

Interventional

Enrollment (Actual)

165

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nijmegen, Netherlands, 6500 HB
        • Radboud University, Department of General Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Registered in one of the general practices participating in the study
  • Diagnosis of COPD, with Global Initiative for Chronic Obstructive Lung Diseases (GOLD) stage I, II or III
  • Age ≥35 years
  • Willing to provide written informed consent

Exclusion Criteria:

  • Very poor prognosis with regard to respiratory condition (GOLD stage IV)
  • Severe co-morbid conditions with a reduced life expectancy
  • Unable to communicate in the Dutch language
  • Objections to one or more of the disease management modes in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: usual care
usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
care at initiative of the patient (usual GP care)
Experimental: monitoring controls
regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Experimental: self-management
disease specific self-management program 'Living Well with COPD'
disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
disease-specific health-related quality of life (HRQoL)
Time Frame: two years
two years

Secondary Outcome Measures

Outcome Measure
Time Frame
the number of exacerbations
Time Frame: two years
two years
generic quality of life
Time Frame: two years
two years
decline post- and pre-bronchodilator (BD) lung function indices
Time Frame: two years
two years
level of respiratory symptoms
Time Frame: two years
two years
satisfaction with the health care received
Time Frame: two years
two years
compliance with (non-) pharmaceutical treatment
Time Frame: two years
two years
direct and indirect medical costs
Time Frame: two years
two years
COPD related self-efficacy
Time Frame: two years
two years
COPD coping styles
Time Frame: two years
two years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Chris van Weel, FRCP, Department of General Practice, Radboud University, Nijmegen, The Netherlands
  • Study Director: Tjard Schermer, PhD, Department of General Practice, Radboud University, Nijmegen, The Netherlands
  • Principal Investigator: Erik Bischoff, MD, Department of General Practice, Radboud University, Nijmegen, The Netherlands

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2005

Primary Completion (Actual)

December 1, 2008

Study Completion (Actual)

December 1, 2008

Study Registration Dates

First Submitted

August 9, 2005

First Submitted That Met QC Criteria

August 9, 2005

First Posted (Estimate)

August 10, 2005

Study Record Updates

Last Update Posted (Estimate)

November 22, 2011

Last Update Submitted That Met QC Criteria

November 21, 2011

Last Verified

November 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • MONC95582
  • ZonMw grant: 945.04.230 (Other Grant/Funding Number: ZonMw)
  • Picasso grant: 005.2004 (Other Grant/Funding Number: Picasso)
  • CMO: 2004/249 (Other Identifier: Medical Ethics Committee)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Diseases, Obstructive

Clinical Trials on care at initiative of the patient (usual GP care)

3
Subscribe